Study summary
A PARP inhibitor delayed progression in men with DNA-repair gene changes
What was tested
Niraparib, a PARP inhibitor pill, or placebo added to abiraterone and prednisone for metastatic castration-sensitive prostate cancer with BRCA or other DNA-repair (HRR) gene alterations.
What they found
- In men with BRCA changes, median progression-free survival was not reached with niraparib vs 26 months without it.
- Anemia (29%, 25% needed a transfusion) and high blood pressure (27%) were the main side effects.
- Survival data were immature but favored niraparib.
What it means
Makes genetic testing at diagnosis more important for men with metastatic disease.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.